세계의 바이오뱅크 시장 : 기회, 성장 요인, 업계 동향 분석 및 예측(2025-2034년)

The Global Biobanking Market was valued at USD 76.2 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 164.5 billion by 2034.

The growing focus on personalized medicine, together with rising investments in genomics and molecular biology research, is strongly propelling market expansion. Biobanks play an essential role in biomedical innovation, enabling the systematic collection, preservation, and analysis of biological specimens such as blood, tissues, and DNA for clinical and therapeutic purposes. Increasing participation in national biobank programs and heightened public awareness of genomic data utilization are reinforcing the industry's importance in modern healthcare. The growing integration of digital platforms and data-sharing technologies is also enhancing global collaboration among research institutes, pharmaceutical companies, and healthcare providers. As the healthcare industry shifts toward data-driven and precision-based medical approaches, biobanking is emerging as a critical infrastructure that supports large-scale population studies, precision diagnostics, and drug discovery. The ongoing development of standardized biobanking protocols, along with automation in storage and sample management, continues to strengthen operational efficiency and improve the accessibility of biological materials for scientific and clinical use.

In 2024, the equipment segment held a 42.5% share, supported by the growing adoption of advanced cryogenic freezers, ultra-low temperature storage units, and automated handling systems. This segment is further divided into sample storage, transport, processing, and analytical equipment. Increasing demand for high-capacity and reliable storage solutions is driven by large-scale genomic research and biopharmaceutical initiatives. Advanced equipment helps maintain biospecimen integrity while reducing manual handling errors, ensuring that samples remain viable for long-term use in both clinical and research environments.

The blood products segment held a 30.3% share in 2024, owing to the extensive use of blood samples in biomarker identification, genetic testing, and clinical diagnostics. The segment benefits from the standardized procedures for collection and preservation that make blood one of the most versatile biospecimens available. Blood samples are widely utilized in a range of studies, including immunology, epidemiology, and metabolic research, which further strengthens their contribution to biobanking. Their importance in disease surveillance, clinical testing, and public health research continues to reinforce this segment's leading position.

North America Biobanking Market held 45.7% share in 2024, supported by a strong presence of established healthcare infrastructure and advanced genomic research initiatives. The U.S. and Canada lead the region's growth, driven by increased focus on precision medicine, cancer research, and advanced biospecimen management practices. Government initiatives and academic collaborations are promoting the expansion of national biobanks, enabling efficient collection and utilization of biological samples for clinical and pharmaceutical research. The high adoption of digital biobanking systems and automation technologies is further enhancing data accessibility and quality, promoting faster progress in personalized therapy development.

Key companies operating in the Global Biobanking Market include Thermo Fisher Scientific, Avantor, Becton, Dickinson and Company, Azenta, Cryoport, BioIVT, Merck & Co., Pfizer, Charles River Laboratories, STEMCELL Technologies, Qiagen, Labcorp, Tecan Trading, PHC Holdings, Eurofins Scientific, Hamilton Company, BioStorage Technologies, Brooks Life Sciences, and Novartis. Leading players in the biobanking market are employing multiple strategies to strengthen their market presence and competitive position. Many are expanding their global biobank networks and investing in automation to streamline sample handling and improve scalability. Strategic mergers, acquisitions, and collaborations are pursued to enhance data integration, sample diversity, and operational efficiency. Companies are also focusing on developing cloud-based biobank management platforms and advanced cryogenic storage solutions to ensure high-quality sample preservation.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product and services trends
  • 2.2.3 Sample type trends
  • 2.2.4 Application trends
  • 2.2.5 Storage type trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Technological advancements in genomics and drug development
    • 3.2.1.2 Increasing demand for personalized medicine
    • 3.2.1.3 Increasing investments in genomic research
    • 3.2.1.4 Integration of bioinformatics tools and advanced data analysis techniques
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with automated systems
    • 3.2.2.2 Issues related to biospecimen sample procurement
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of decentralized and mobile biobanking models
    • 3.2.3.2 Expansion into multi-omics and longitudinal health data integration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Future market trends
• 3.6 Technological landscape
  • 3.6.1 Current technologies
  • 3.6.2 Emerging technologies
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product and services, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Equipment
  • 5.2.1 Storage equipment
  • 5.2.2 Sample analysis equipment
  • 5.2.3 Sample processing equipment
  • 5.2.4 Sample transport equipment
• 5.3 Consumable
  • 5.3.1 Storage consumables
  • 5.3.2 Analysis consumables
  • 5.3.3 Processing consumables
  • 5.3.4 Collection consumables
• 5.4 Service
  • 5.4.1 Storage services
  • 5.4.2 Processing services
  • 5.4.3 Transport services
  • 5.4.4 Supply services
• 5.5 Software

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Blood products
• 6.3 Human tissues
• 6.4 Cell lines
• 6.5 Nucleic acids
• 6.6 Biological fluids
• 6.7 Human waste products
• 6.8 Other sample types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Regenerative medicine
• 7.3 Life-science research
• 7.4 Clinical research
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Storage Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Automated storage
• 8.3 Manual storage

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Biotechnology & pharmaceutical companies
• 9.3 Contract research organizations (CROs)
• 9.4 Academic & research institutes
• 9.5 Hospitals

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Avantor
• 11.2 Azenta
• 11.3 Becton, Dickinson and Company
• 11.4 BioIVT
• 11.5 BioStorage Technologies
• 11.6 Brooks Life Sciences
• 11.7 Charles River Laboratories
• 11.8 Cryoport
• 11.9 Eurofins Scientific
• 11.10 Hamilton Company
• 11.11 Labcorp
• 11.12 Merck & Co.
• 11.13 Novartis
• 11.14 Pfizer
• 11.15 PHC Holdings
• 11.16 Qiagen
• 11.17 STEMCELL Technologies
• 11.18 Tecan Trading
• 11.19 Thermo Fisher Scientific